Alumis Inc. reported total assets of $488.7 million as of September 30, 2026, supported by a significant increase in marketable securities following its IPO. The company is focused on the development of envudeucitinib (envu) for plaque psoriasis, with plans to submit a New Drug Application by the end of 2026.
Park Dental Partners reported third quarter 2026 revenue of $64.9 million, a 6% increase year-over-year driven by reimbursement trends and acquisitions. Net income rose 36.1% to $1.7 million, although diluted EPS decreased to $0.27 compared to $0.72 in the prior-year period. The company also highlighted the completion of the Village Family transaction, expanding its network into a fourth state.
Term
Q3 2026
“Third-quarter revenue increased 6%, supported by same-practice growth, an expanding affiliated doctor base and contributions from recently acquired practices. We have made meaningful progress adding clinical capacity and strengthening our platform, and our focus now is converting that capacity and revenue growth into improved productivity and stronger earnings performance.”
Pete Swenson, Chief Executive Officer and Chair of the Board of Directors
“The completion of the Village Family transaction represents an important step in our growth strategy and extends our affiliated practice network into a fourth state. We remain focused on disciplined integration, supporting our affiliated practices and executing against the opportunities already within our business.”
Pete Swenson, Chief Executive Officer and Chair of the Board of Directors
Carlyle Private Equity Partners Fund, L.P. reported total assets of $477.3 million as of September 30, 2026, a significant increase from $59.0 million at the end of 2025. The fund's investment portfolio grew to a fair value of $280.4 million, supported by substantial cash and cash equivalents of $194.2 million.
ProKidney Corp. reported third quarter 2026 financial results, ending the period with $141.9 million in cash and marketable securities to fund operations into mid-2027. The company remains on track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint topline results in Q2 2027. R&D expenses increased to $40.8 million, driven by clinical study and manufacturing costs for the ongoing rilparencel program.
Term
Q3 2026
“The third quarter marked continued progress for ProKidney, with PROACT 1 advancing toward full enrollment and our pivotal eGFR slope topline readout remaining on track for the second quarter of 2027. The data presented at Kidney Week further build the mechanistic and clinical evidence supporting rilparencel and provide a more cohesive picture of how it may stabilize kidney function. Together, these advances reinforce our confidence as we approach this important Phase 3 readout and continue our mission to transform the treatment of advanced CKD.”
Dragonfly Energy reported Q3 2026 net sales of $12.2 million, down 23.8% year-over-year due to softness in the RV market, though heavy-duty trucking revenue more than doubled sequentially. The company completed the acquisition of the Dakota Lithium brand during the quarter and expects to reach approximately breakeven Adjusted EBITDA in Q4 2026.
Term
Q3 2026
“Third quarter heavy-duty trucking revenue more than doubled sequentially to $1.3 million, in line with our August outlook, driven by expanding commercial fleet adoption. For the first time, we received orders from fleets moving directly into commercial deployment without a pilot program, reflecting the credibility we have established through years of field validation.”
Prairie Operating Co. reported a significant increase in revenues to $311.8 million for the nine months ended September 30, 2026, compared to $158.6 million in the prior year. However, the company incurred a net loss of $92.6 million for the period, driven largely by a $266.2 million loss on derivatives and increased operating expenses.
Electra Therapeutics reported third quarter 2026 financial results and provided updates on its SIRP-targeting portfolio, including the advancement of ipsoprubart in a global registrational program for sHLH. The company recently completed a $350 million IPO to fund its clinical pipeline, with several data readouts and enrollment milestones expected throughout 2027.
“Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion. Our deep expertise in SIRP biology and proprietary library of SIRP-targeting antibodies enable us to selectively address distinct pathogenic immune cell populations, creating therapeutic optionality across immune-mediated diseases and cancer.”
Kathy Dong, PharmD, MBA, President and Chief Executive Officer
CytoSorbents reported Q3 2026 financial results, highlighting the achievement of operating cash flow breakeven (excluding restructuring payments). Revenue grew 3% to $9.7 million, while operating loss improved by 59% to $1.2 million due to disciplined cost management and improved gross margins.
Term
Q3 2026
“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments. This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business.”
Fulcrum Therapeutics is currently pursuing a merger with Slate Medicines, Inc. while undergoing significant restructuring, including the cessation of clinical development for pociredir and a workforce reduction. The company reported a net loss of $56.0 million for the nine months ended September 30, 2026, and currently has no product candidates in active clinical development.
System1, Inc. reported its financial results for the third quarter ended September 30, 2026, disclosing revenue of $25.95 million. The company recorded a significant net loss of $51.28 million for the quarter, impacted by a $63.6 million impairment charge on goodwill and other long-lived assets.
For the nine months ended September 30, 2026, Longeveron Inc. reported a net loss of $16.9 million, a slight improvement from the $17.3 million loss in the prior year period. Total revenues decreased slightly to $0.8 million, while the company strengthened its cash position to $7.2 million through private placements and warrant exercises.
Birchtech Corp. reported a net loss of $4.6 million for the nine months ended September 30, 2026, compared to a $2.4 million loss in the prior year period, despite a 23% increase in product revenue. The company significantly strengthened its balance sheet during the period, ending with $10.8 million in cash following a common stock issuance that raised approximately $14.2 million in net proceeds.
Franklin Covey Co. reported fiscal 2026 consolidated revenue of $261.5 million, a 2% decrease from the prior year, while net income improved to $4.9 million. Despite lower revenues in the Enterprise Division due to macroeconomic uncertainties and geopolitical tensions, Adjusted EBITDA increased slightly to $28.9 million, supported by restructuring activities and cost reduction efforts.
Holistic Asset Finance Group Co., Ltd. reported a significant increase in revenue to $4.94 million for the nine months ended September 30, 2026, compared to $1.69 million in the prior year. The company achieved a small net income of $2,436 for the period, recovering from a net loss of $36,331 in 2025, primarily driven by its export trading and marketing services operations.
AnaptysBio reported financial results for the fiscal first quarter ended September 30, 2026, highlighted by $1.0 billion in global net sales of Jemperli for the first nine months of 2026. The company is currently awaiting a court judgment in its litigation against GSK and Tesaro, where it is seeking the reversion of Jemperli rights as a remedy.
Counterparty
GSK
“Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications.”
Daniel Faga, president and chief executive officer
“We remain focused on protecting and returning the value of our financial collaborations to shareholders as we approach a judgment in our litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027 and the FDA target action date for Quimilza in December 2026.”
Daniel Faga, president and chief executive officer
Polaryx Therapeutics reported a net loss of $7.3 million for the nine months ended September 30, 2026, compared to $7.5 million in the prior year period. The company maintains a going concern warning due to recurring losses and negative operating cash flows, though it successfully raised $9.8 million through common stock issuances during the period.
MultiSensor AI Holdings reported Q3 2026 financial results, highlighted by a 43% increase in software revenue which now represents 58% of total revenue. The company reported a net loss of $1.9 million on total revenue of $1.5 million, while maintaining a debt-free balance sheet with $20.4 million in cash.
Term
Q3 2026
“Our relationship with our largest distribution customer shows how we believe this business scales. Programs that began in Europe continue to grow, with solar performance monitoring now extending to additional European sites, and have led to that customer’s first 14-site rollout in North America. Each step has been built on results their maintenance teams have seen in their own facilities, and we are seeing that same path open up with customers like Manchester Airports Group.”
Asim Akram, Chief Executive Officer
“Our revenue mix is shifting the way we intended. Software subscriptions are now the majority of our revenue for the quarter, and recurring revenue continues to grow, which gives us better visibility into the periods ahead. We paired that with disciplined spending, and with help from strong collections our cash use slowed meaningfully in the third quarter. With no debt, we have the balance sheet to keep investing in recurring revenue.”
Beeline Holdings, Inc. reported a net loss of $13.1 million for the nine months ended September 30, 2026, compared to a $15.0 million loss in the prior year period. Total net revenues grew significantly to $8.3 million from $5.3 million, driven by higher gains on loan sales and origination fees, though operating expenses also increased to $21.8 million.
Marpai, Inc. reported a net loss of $11.1 million for the nine months ended September 30, 2026, with revenue declining to $13.0 million from $14.1 million in the prior year period. The company improved its stockholders' deficit to $29.8 million, aided by the issuance of $12.1 million in privately placed preferred stock.
Horizon Kinetics Holding Corp reported a net loss attributable to the company of $18.35 million for the third quarter of 2026, compared to a net income of $7.24 million in the prior year period. Total revenue remained relatively flat at $18.03 million, but the bottom line was significantly impacted by investment losses within consolidated investment products and unrealized losses on investments.
ProKidney Corp. reported a net loss available to Class A common stockholders of $84.1 million for the nine months ended September 30, 2026, compared to $49.8 million in the prior year period. The increase in loss was primarily driven by higher research and development expenses, which rose to $110.8 million as the company continues its clinical programs.
Energous Corporation reported Q3 2026 revenue of $3.4 million, a 167% increase year-over-year, driven by commercial adoption of its wireless power technology. Year-to-date revenue of $9.6 million has already surpassed the company's total revenue for the full year 2025. The company reported a GAAP net loss of $2.5 million for the quarter while noting significant improvements in gross margin as production scales.
Term
Q3 2026
“Our third quarter results reflect continued momentum in the commercial adoption of Energous’ technology, with revenue growing significantly year over year and our year-to-date revenue performance already surpassing full-year 2025.”
Mallorie Burak, CEO and CFO of Energous
“We also made meaningful progress in improving gross margins as we continue to scale production to better support customer demand. Looking ahead, we see significant opportunity to build on this momentum as enterprises increasingly recognize the value of continuous, real-time visibility into their operations.”
Atrium Therapeutics reported third quarter 2026 financial results, highlighting the dosing of the first patient in its Phase 1/2 clinical trial for ATR 1072. The company also closed a $50 million private placement, extending its cash runway through 2028 with a pro-forma cash balance of $293.6 million.
Term
Q3 2026
“The last eight months have marked many firsts for Atrium, building toward our transition to a clinical stage company with the initiation of Corventis, the first clinical trial ever to target the root cause of PRKAG2 syndrome.”
Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics
“Our $50 million private placement with leading institutional investors extends our cash runway through 2028. With ~$290 million on our balance sheet, we are well positioned to deliver on our upcoming milestones.”
Brendan Winslow, Chief Financial Officer of Atrium Therapeutics
Blackstone Private Real Estate Credit and Income Fund reported total assets of $2.57 billion as of September 30, 2026, a significant increase from $1.58 billion at year-end 2025. Net investment income for the nine months ended September 30, 2026, was $65.3 million, driven by interest income from its growing portfolio of senior loans and debt securities.
ADARx Pharmaceuticals reported a significant increase in cash and cash equivalents to $570.6 million as of September 30, 2026, following its initial public offering and concurrent private placement. The company is advancing a clinical pipeline including onvuzosiran (Phase 3) and agazisiran (Phase 2), supported by a major collaboration with AbbVie that contributed to $326.4 million in total deferred revenue.
Once Upon a Farm, PBC reported net sales of $247.2 million for the nine months ended September 30, 2026, a significant increase from $176.7 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $24.6 million for the first nine months of 2026, though this was an improvement over the $39.8 million net loss reported for the same period in 2025.
As of September 30, 2026, SKYX Platforms Corp. reported a significant increase in cash and cash equivalents to $19.4 million, up from $8.1 million at the end of 2025. Total assets grew to $63.3 million, while total liabilities decreased to $49.3 million, primarily driven by reductions in operating lease liabilities and convertible notes.
Vylor Inc. (formerly the Seed Business of Corteva) became an independent public company on October 1, 2026, following a tax-free spin-off. For the nine months ended September 30, 2026, the company reported net sales of $13,742 million and net income attributable to the company of $1,311 million, compared to $13,491 million and $1,646 million respectively in the prior year period.
AmpliTech Group reported Q3 2026 revenue of $6.58 million, an 8.0% increase year-over-year, driven by strong growth in its Spectrum Semiconductor Materials distribution business. The company narrowed its net loss sequentially to $1.89 million and reported a significant backlog surpassing $52 million as of October 2026.
VolitionRx reported financial results for the third quarter of 2026, highlighting progress in its Nu.Q platform across sepsis, lung cancer, and veterinary diagnostics. The company noted the launch of the French government-funded DETECSEPS program and active licensing discussions for its Capture-Seq technology in the liquid biopsy market.
Term
Q3 2026
“It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q® platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.”
Cameron Reynolds, President and Group Chief Executive Officer